Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are reverting to a Neutral recommendation on Regeneron Pharmaceuticals (REGN - Analyst Report) as we believe that all the positive news that led to our previous Outperform recommendation on the stock are reflected in the current price.

Regeneron performed impressively in the second quarter of 2012, driven by strong sales of its eye drug Eylea. Sales of Eylea launched in the US on November 21, 2011, for the treatment of the neovascular form of age-related macular degeneration (wet AMD) climbed 57% sequentially to $194 million in its second full quarter on the market.

Encouraged by the strong performance of Eylea, the company increased its forecast for 2012 US Eylea sales for the second successive quarter. Management now expects the eye drug to record 2012 sales in the range of $700-$750 million as opposed to the previously forecasted range of $500-$550 million. We, too, expect Eylea to continue performing well.

The label expansion of Eylea in the US for the treatment of macular edema following central retinal vein occlusion has further boosted its sales potential. Regeneron is studying Eylea for other indications as well such as diabetic macular edema (phase III) and branch retinal vein occlusion (phase III). Moreover, the US approval of Zaltrap for treating previously treated patients suffering from metastatic colorectal cancer is another positive for Regeneron. Zaltrap is under review in Europe for the indication. Zaltrap is being studied for other oncology indications as well.

However, we are mindful of the regulatory/pipeline setbacks at Regeneron. In July 2012, Regeneron suffered a setback in its efforts to expand the label of its marketed drug Arcalyst (cryopyrin-associated periodic syndromes). The US Food and Drug Administration (FDA) declined to approve Arcalyst for preventing gout flares in patients initiating uric acid-lowering therapy on the basis of the submitted data and issued a complete response letter.

Moreover, in April 2012, Regeneron and partner Sanofi (SNY - Analyst Report) suffered a pipeline setback when Zaltrap performed disappointingly in a phase III study which evaluated the candidate as a first-line therapy for metastatic castration-resistant prostate cancer. Similar setbacks have the potential to pull down Regeneron.

We note that all three marketed products at Regeneron – Arcalyst, Eylea and Zaltrap face competition in their respective areas. While Arcalyst is facing competition from Novartis’ (NVS - Snapshot Report) Ilaris for cryopyrin-associated periodic syndromes, Eylea competes with Roche (RHHBY - Analyst Report)/Novartis’ Lucentis in the wet AMD space and Zaltrap competes primarily with Roche’s Avastin in the colorectal cancer space.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%